All lobbying filings
W STRATEGIES, LLC
W STRATEGIES, LLC filed a Q4 termination report for SUPERNUS PHARMACEUTICALS FKA SAGE THERAPEUTICS on January 20, 2026, reporting $50,000 in lobbying income.
Lobbying for SUPERNUS PHARMACEUTICALS FKA SAGE THERAPEUTICS · A clinical-stage biopharmaceutical company.
Filing · LD-2 quarterly report
Q4 termination
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
Massachusetts
Representation ended
Dec 31, 2025
The registrant reported terminating its work for this client.
Lobbying activity
1
Education and awareness of mental health issues especially as it relates to access for postpartum depression treatment and major depressive disorder.